P
Patricia F. Walker
Researcher at University of Minnesota
Publications - 89
Citations - 2798
Patricia F. Walker is an academic researcher from University of Minnesota. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 61 publications receiving 2089 citations. Previous affiliations of Patricia F. Walker include DuPont & Humboldt University of Berlin.
Papers
More filters
Journal ArticleDOI
Evidence-Based Policies on Migration and Global Health are Essential to Maintain the Health of Those Inside and Outside the United States
Philip J. Rosenthal,Daniel G. Bausch,Stephen Higgs,N. Regina Rabinovich,David R. Hill,Christopher V. Plowe,Karen A. Goraleski,Patricia F. Walker +7 more
TL;DR: This book aims to provide a history of Tropical Medicine and Hygiene in South East Asia from 1910 to the present day and describes its development up to and including the period of drought in the region from 1950 to 1997.
Journal ArticleDOI
The cost of global connectivity: Faster and more efficient spread of antimicrobial resistance by international travelers – A controversial commentary
Christine M. Thomas,Olaf H. Morkeberg,Patricia F. Walker,Patricia F. Walker,William M. Stauffer +4 more
TL;DR: In this article, the authors pointed out that international travelers are proportionately much more likely to perpetuate AMR spread due to the vastly greater volume combined with the increasing efficiency and speed at which they travel.
Journal ArticleDOI
Hepatitis B Evaluation and Linkage to Care for Newly Arrived Refugees: A Multisite Quality Improvement Initiative.
Colleen Payton,Colleen Payton,Malini B. DeSilva,Janine Young,Katherine Yun,Katherine Yun,Deborah Aragon,Lori Kennedy,Carol Tumaylle,Daniel White,Patricia F. Walker,Emily S. Jentes,Blain Mamo +12 more
TL;DR: Standardized reflex HBV testing and specialist referral should be prioritized at the initial screening due to the association with timely care.
Journal ArticleDOI
P666: acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 5-year follow-up of elevate-tn
Jeff P. Sharman,Miklos Egyed,Wojciech Jurczak,Alan Z. Skarbnik,Katan Patel,Ian W. Flinn,Manali Kamdar,Talha Munir,Renata Walewska,Laura Fogliatto,Yair Herishanu,Versha Banerji,George A. Follows,Patricia F. Walker,Karin Karlsson,Paolo Ghia,Annelies Janssens,Florence Cymbalista,Emmanuelle Ferrant,William G. Wierda,Veerendra Munugalavadla,T. Yu,M Wang,Jennifer A. Woyach +23 more
TL;DR: In this article , the authors reported superior efficacy of acalabrutinib (A) ± obinutuzumab (O) vs O + chlorambucil (Clb) in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL) at 28.3 and 46.9 months median follow-up.
Journal ArticleDOI
Let's Eliminate Diseases, Not Institutes: The Case for the Fogarty International Center.
TL;DR: It is disappointing that the FY2018 presidential budget recommends an 18% cut in support for the NIH, and particularly noteworthy that the president’s budget took the unusual step of singling out one of the 27 institutes and centers of the NIH for complete elimination, the Fogarty International Center (FIC).